Cargando…
TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model
BACKGROUND: Castrate Resistant Prostate Cancer (CRPC) is an advanced disease resistant to systemic traditional medical or surgical castration, and resistance is primarily attributed to reactivation of AR through multiple mechanisms. TMPRSS2-ERG fusions have been shown to regulate AR signaling, inter...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6802314/ https://www.ncbi.nlm.nih.gov/pubmed/31638934 http://dx.doi.org/10.1186/s12885-019-6185-0 |